drugset
drugset / Trial / NCT03576131

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

NCT03576131 ↗

Phase 1/2 Terminated 48 enrolled Genmab
NaSequentialOpen-labelTreatment

Summary

The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors

Timeline

Start
2018-04-30
Primary completion
2021-10-12
Completion
2021-10-12

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject GEN1029 Unknown — Intravenous

Indications

colorectal cancer gastric cancer malignant pancreatic neoplasm non-small cell lung carcinoma renal cell carcinoma triple-negative breast carcinoma urothelial carcinoma